Part, Chapter, Paragraph
1 II, 5. 5. 3| accurate comparative data on prescribing patterns and respective
2 II, 5. 5. 3| reflecting this gap are the prescribing practice, the provision
3 II, 5. 5. 3| atypical neuroleptics” – the prescribing practice also shows significant
4 II, 5. 5. 3| time (years 1993 – 2002) in prescribing atypicals (Knapp et al,
5 II, 6. 3. 2| Europe; the highest user prescribing three times more antibiotics
6 II, 9. 2. 3| Excellence (NICE) guidance on prescribing corticosteroids states “
7 IV, 11. 1. 5| minimal effect on physician prescribing behaviour (Hetlevik et al,
8 IV, 11. 1. 5| been poor compliance with prescribing guidelines for many reasons:
9 IV, 11. 1. 5| al, 2000).~ ~Regulating prescribing patterns is another method
10 IV, 11. 1. 5| appropriateness of care. Prescribing patterns differ significantly
11 IV, 11. 1. 5| have been made to monitor prescribing quality, such as the use
12 IV, 11. 1. 5| Appropriateness Index which assesses prescribing suitability (Mossialos et
13 IV, 11. 1. 5| et al, 2004). In the UK, prescribing data are used to provide
14 IV, 11. 1. 5| information on their current prescribing in an attempt to encourage
15 IV, 11. 1. 5| effective and economical prescribing.~ ~Pharmacies play a role
16 IV, 11. 1. 5| study highlighted errors in prescribing medications as the most
17 IV, 11. 3. 2| practice or collective prescribing budgets in the UK and Germany,
18 IV, 11. 3. 2| in the UK and Germany, or prescribing guidelines in France. Evidence
19 IV, 11. 6. 5| to Errors in Medication Prescribing." Journal of the American
20 IV, 11. 6. 5| Provider incentives and prescribing in Europe." Expert Review
21 IV, 11. 6. 5| Financial incentives and prescribing. Regulating Pharmaceuticals
